Bain Capital sells 6% stake in Korea’s Classys via block deal for $163 million

The deal marks a partial retreat after Bain’s failed bid to sell control of Classys amid lukewarm investor interest

Commercial for Classys’ beauty device Shurink Universe (File photo by Classys)
Commercial for Classys’ beauty device Shurink Universe (File photo by Classys)
Jong-Kwan Park 2
May 19, 2025 (Gmt+09:00) pjk@hankyung.com
Private equity

Bain Capital LP has offloaded a 6% stake in South Korean medical aesthetics company Classys Inc. through a block trade, raising 228 billion won ($163 million) as the US private investment firm scaled back its position after a stalled exit attempt.

Classys said in a regulatory filing on Friday that Bain Capital, its largest shareholder, sold 3.93 million shares at 57,915 won apiece, representing a 10.9% discount to Classys’ closing price on Thursday.

The transaction reduced Bain’s holding in the Kosdaq-listed company to 54.16% from 60.16%, according to the filing.

Classys is a Korean medical aesthetic device maker
Classys is a Korean medical aesthetic device maker

The deal marks a partial retreat as Bain’s earlier efforts to sell control of the company failed to attract sufficient investor interest.

Last October, the Boston-based buyout firm appointed JPMorgan and Citigroup Global Markets Inc. as advisors to explore the sale of its entire stake, but potential buyers balked at the valuation, industry sources said.

Classys' products on display at an exhibition
Classys' products on display at an exhibition

LUKEWARM APPETITE FOR FULL BUYOUT

Sources said Bain’s block sale reflects a pivot toward recovering some of its capital in the face of lukewarm appetite for a full buyout.

“There has been limited interest at the asking price for a full acquisition,” said a Seoul-based banker familiar with the matter. “The block trade allows Bain to reduce exposure while still maintaining control.”

In early Monday trade, shares of Classys were down 0.7% at 60,050 won versus the Kosdaq index’s 1.6% fall.

South Korea's Classys provides medical aesthetic devices to over 70 countries (Screenshot captured from its website)
South Korea's Classys provides medical aesthetic devices to over 70 countries (Screenshot captured from its website)

Classys, founded in 2007, is known for the beauty device Shurink Universe, which uses high-intensity focused ultrasound (HIFU) for skin tightening. The company is the unrivaled leader in the Korean HIFU treatment device market, controlling more than 55% of the segment.

Bain bought a majority stake in Classys for 670 billion won in 2022.

The partial divestment underscores the challenges faced by global private equity firms in exiting their investments in Korea, where a valuation gap and weak M&A sentiment have hampered deal activity in recent months.

Classys' products
Classys' products

Korean private equity firms are also said to be reluctant to acquire full control of Classys in the aftermath of MBK Partners Ltd.’s handling of Homeplus Co., a Korean retailer that filed for court receivership, sources said.

In late March, global private equity giants such as KKR & Co., the Carlyle Group and Hillhouse Capital Group Holdings Ltd. showed interest in acquiring a stake in Classys, sources said.

Write to Jong-Kwan Park at pjk@hankyung.com

In-Soo Nam edited this article.

KKR, Carlyle, Hillhouse race to buy Korean beauty device maker Classys

KKR, Carlyle, Hillhouse race to buy Korean beauty device maker Classys

Ad for Classys’ beauty device Shurink Universe (File photo by Classys) Global private equity giants such as KKR & Co., Carlyle Group and Hillhouse Capital Group Holdings are vying to acquire Classys Inc. as the South Korean medical aesthetic device maker is enjoying strong margins ami

Bain Capital puts beauty device maker Classys on market

Bain Capital puts beauty device maker Classys on market

Classys' products on display at an exhibition Bain Capital has embarked on the process to sell a majority stake in Classys Inc., a South Korean medical aesthetic device maker. The deal is estimated at 3 trillion won ($2.2 billion), or about four times its purchase price, according to people wit

Lotte Chemical, Bain Capital among bidders for Korea’s Iljin Materials

Lotte Chemical, Bain Capital among bidders for Korea’s Iljin Materials

Iljin Materials' elecfoil The much-touted sale of a controlling stake in Iljin Materials Co., a leading South Korean battery materials maker, is flagging as big spenders are showing less interest amid the weak local stock market.According to investment banking sources on Friday, Lotte Chemical

Bain Capital seals 3rd beauty M&A deal in S.Korea

Bain Capital seals 3rd beauty M&A deal in S.Korea

Classys' products on display at a 2021 exhibition Bain Capital on Thursday agreed to buy a majority stake in South Korea's medical aesthetic device manufacturer Classys Inc. for 670 billion won ($560 million), marking its third acquisition of a Korean beauty company.The acquisition followed the